Nadia Waheed Sells 7,863 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Nadia Waheed sold 7,863 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $71,081.52. Following the completion of the transaction, the insider directly owned 318,417 shares in the company, valued at $2,878,489.68. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ocular Therapeutix Trading Down 1.6%

NASDAQ:OCUL opened at $6.88 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44. The company has a market cap of $1.50 billion, a PE ratio of -4.78 and a beta of 0.90. The firm has a 50-day moving average of $11.04 and a 200-day moving average of $11.74.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The company had revenue of $13.25 million for the quarter, compared to analysts’ expectations of $16.13 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. Ocular Therapeutix’s quarterly revenue was down 22.4% on a year-over-year basis. As a group, equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Trending Headlines about Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 (AXPAXLI) showed statistical superiority on the trial’s primary vision endpoint versus Regeneron’s Eylea in the Phase 3 SOL‑1 study, validating Ocular’s pathway toward an FDA submission and potential commercial opportunity in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: An analyst reaffirmation and bullish price target — Chardan Capital reissued a “buy” with a $21 target — gives investors a sizable upside thesis should regulatory and commercial questions be resolved. Benzinga
• Neutral Sentiment: Ocular released topline SOL‑1 results and management commentary; while topline reads positive, investors are awaiting full data (subgroup analyses, comparator details, safety, and durability) before repricing longer‑term expectations. Ophthalmology Times
• Negative Sentiment: Market reaction was sharply negative on release day: coverage highlighted the benefit as “modest” and noted that some comparisons used a lower‑dose/less‑favorable Eylea arm, creating doubts about clinical meaningfulness and commercial differentiation. That skepticism appears to have driven heavy selling. MSN article on market reaction
• Negative Sentiment: Significant insider selling was disclosed (including large sales by Pravin Dugel and others, plus Nadia Waheed’s sale), which can amplify downward pressure and signal near‑term insider liquidity actions to the market. SEC filing for insider sales
• Negative Sentiment: Johnson Fistel’s public investor outreach flags an investigation into possible securities claims against Ocular’s officers — news that can increase legal uncertainty and weigh on sentiment until resolved. GlobeNewswire: Johnson Fistel announcement

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on OCUL shares. Needham & Company LLC restated a “buy” rating and set a $20.00 price target on shares of Ocular Therapeutix in a report on Monday, December 8th. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research note on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.00.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its position in Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,242 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Ocular Therapeutix by 1.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 1,314 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,392 shares during the last quarter. Trust Co. of Vermont raised its stake in Ocular Therapeutix by 24.3% in the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,750 shares during the period. Finally, Profund Advisors LLC lifted its holdings in Ocular Therapeutix by 9.9% during the third quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 2,272 shares during the last quarter. 59.21% of the stock is owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.